Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (2713)	1/29/2001 11:10:29 AM
From: Ian@SI	Respond to of 52153

Call may not help much. Until the study is fully unblinded, ALXN won't have much insight into the 2 week vs monthly.

To: Biomaven who wrote (2713)	1/29/2001 12:47:15 PM
From: Ian@SI	Respond to of 52153

Alexion Pharm (ALXN) 71 -3 3/4: USB Piper Jaffray upgrades to STRONG BUY from BUY and raises price target to $160 as company succeeds in Phase II Rheumatoid study. +++++++++++++ Peter, S&P hated the results according to Joe Kernan on CNBC. I haven't seen the report so I don't know. Kernan has been wrong before in interpreting what analysts are saying. ;^) The trial population does seem a little strange. I would have thought best improvement would be seen in patients with the more advanced symptoms especially given the degree to which patient's subjective judgment is being used to assess efficacy. Again, wouldn't efficacy as measured by CRP be best shown in the more advanced cases? And wouldn't the company want to know this stuff to better design their PhIII? Ian.